CTRI/2021/01/030388
Active, not recruiting
Phase 2
An Open labeled Multicentric Pilot study to study the safety and efficacy of Silvernova skin cream (20 ppm) in ambulant patients with selected skin diseases
Viridis BioPharma Pvt Ltd0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Viridis BioPharma Pvt Ltd
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male and female aged 18 to 65 who are suffering from mild or moderate fungal infection like intertrigo, tinea, bullous skin disorders like pemphigus or pemphigoids and intense skin care and repair post cosmetic skin procedures including laser procedures, peels. Based on appearance of lesions, Investigators will have the judgement on fungal infection being mild, moderate, or severe.
- •2\.Willing to give informed consent
Exclusion Criteria
- •1\.Patients who are suffering from any major systemic illnesses.
- •2\.Patients Participation in any other clinical trials evaluating investigational pharmaceuticals orbiologics within 3 months or devices within 30 days of admission to the study.
- •3\.Cases with secondary infections will be excluded from this study.
- •4\.Severe cases of fungal infection.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Multicenter, Open-Label, Pilot Study to Explore the Safety and Efficacy of Intravenous Bortezomib in Patients with Hepatitis C - ViroLogik CT-02repeated dose treatment with Bortezomib in patients with chronic HCV infectionMedDRA version: 9.1Level: LLTClassification code 10002724Term: Anti-HCV positiveEUCTR2008-000495-24-DEViroLogik GmbH10
Active, not recruiting
Not Applicable
A multicenter open label randomized pilot study, to compare retinal nerve fiber layer thickness measured by Optical Coherence Tomography after treatment with daily 20 mg glatiramer acetate subcutaneously or after no treatment, in patients with a clinical isolated syndrome, other than optic neuritis or early relapsing remitting multiple sclerosis patients - OCTclinical isolated syndromeMedDRA version: 9.1Level: LLTClassification code 10028248Term: Multiple sclerosis-like syndromeEUCTR2009-013129-41-NLAmphia Ziekenhuis
Completed
Not Applicable
A pilot, open-label, multicentre study to investigate the safety of calf intestine alkaline phosphatase in patients with fulminant active ulcerative colitis refractory to steroid therapyFulminant ulcerative colitisDigestive SystemUlcerative colitis unspecifiedISRCTN64619216AM-Pharma B.V. (The Netherlands)20
Completed
Phase 4
A study to assess the safety and efficacy of TumsUP® oral drops in the treatment of baby colic.Health Condition 1: R108- Other abdominal painCTRI/2020/04/024552Zuventus Healthcare Limited200
Completed
Phase 4
A observational study to evaluate the efficacy and safety of Ranibizumab in patients with visual impairment due to Diabetic Macular Edema(DMEHealth Condition 1: null- Patients with visual impairment due to Diabetic Macular EdemaCTRI/2015/06/005945ovartis Healthcare Pvt Ltd